Answers are grounded in this paper and cite their sources.
Whereas inhibition of 5-lipoxygenase will result in global inhibition of the production of leukotrienes, antagonism of leukotrienes at their tissue receptors provides selective inhibition of actions mediated by distinct classes of receptors (Table 1). The different profiles of biological activities for leukotriene B 4 (LTB 4 ) and the cysteinyl-leukotrienes suggested that the two main classes of leukotrienes possessed different classes of receptors, and pharmacological investigations have indeed confirmed this. The receptors for LTB 4 are called BLT receptors whereas the receptors for cysteinyl-leukotrienes are designated CysLT receptors (1). With regard to antagonism of the CysLT receptors, studies support some heterogeneity and at least two main subgroups of receptors have therefore been proposed, CysLT 1 and CysLT 2 . It is likely that there are more subdivisions to consider, but as the CysLT receptors remain to be cloned, this classification so far remains the framework for our understanding. Although there are experimental compounds that may block several of the known leukotriene receptors (Table 1), clinically useful drugs have so far been developed only against the main receptor for cysteinyl-leukotrienes in the human lung. This receptor is now called the CysLT 1 receptor but was previously known as the LTD 4 receptor. This article serves to give an overview of the leukotriene receptors, with particular attention to the virgin state of knowledge in this area.
No takes yet. Share an insight, caveat, or question.
Sven‐Erik Dahlén (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: